Kenmare Capital Partners L.L.C. grew its holdings in shares of Allergan plc (NYSE:AGN) by 1,482.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 53,000 shares of the company’s stock after purchasing an additional 49,650 shares during the period. Allergan accounts for 9.5% of Kenmare Capital Partners L.L.C.’s portfolio, making the stock its 4th biggest position. Kenmare Capital Partners L.L.C.’s holdings in Allergan were worth $8,670,000 as of its most recent SEC filing.
Several other large investors have also modified their holdings of AGN. Avestar Capital LLC bought a new position in shares of Allergan during the fourth quarter worth about $113,000. Focused Wealth Management Inc grew its position in shares of Allergan by 4,444.4% during the fourth quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock worth $134,000 after acquiring an additional 800 shares during the last quarter. BB&T Investment Services Inc. grew its position in shares of Allergan by 1,308.2% during the third quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock worth $139,000 after acquiring an additional 641 shares during the last quarter. Acropolis Investment Management LLC bought a new position in shares of Allergan during the fourth quarter worth about $153,000. Finally, Field & Main Bank bought a new position in shares of Allergan during the fourth quarter worth about $155,000. 78.40% of the stock is currently owned by institutional investors.
Allergan plc (AGN) opened at $163.50 on Wednesday. Allergan plc has a 12-month low of $142.81 and a 12-month high of $256.80. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.06 and a current ratio of 1.16. The firm has a market cap of $55,180.00, a PE ratio of -13.61, a PEG ratio of 1.12 and a beta of 1.29.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be given a dividend of $0.72 per share. This is a positive change from Allergan’s previous quarterly dividend of $0.70. The ex-dividend date of this dividend is Tuesday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.76%. Allergan’s dividend payout ratio (DPR) is -24.02%.
In other Allergan news, Director Joseph H. Boccuzi acquired 900 shares of Allergan stock in a transaction dated Monday, March 5th. The stock was bought at an average price of $143.42 per share, for a total transaction of $129,078.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, insider William Meury sold 58,879 shares of the firm’s stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $160.62, for a total transaction of $9,457,144.98. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 7,200 shares of company stock valued at $1,108,267. Insiders own 0.36% of the company’s stock.
Several equities analysts have recently commented on AGN shares. Argus lowered shares of Allergan from a “buy” rating to a “hold” rating and lowered their price target for the stock from $256.80 to $160.07 in a research report on Thursday, December 7th. Deutsche Bank restated a “buy” rating and set a $215.00 price target on shares of Allergan in a research report on Tuesday, January 9th. Barclays upgraded shares of Allergan from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $220.00 to $230.00 in a research report on Monday, January 29th. They noted that the move was a valuation call. Zacks Investment Research lowered shares of Allergan from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Finally, Vetr lowered shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 price target for the company. in a research report on Wednesday, December 6th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $225.03.
TRADEMARK VIOLATION WARNING: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/14/kenmare-capital-partners-l-l-c-raises-holdings-in-allergan-plc-agn.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.